利福布汀联合抗病毒药物治疗结核病合并艾滋病的效果观察  

Observation on the Effect of Rifabutin Combined with Antiviral Drugs in the Treatment of Tuberculosis Complicated with AIDS

作　　者：林晓贞 许晓明 LIN Xiaozhen;XU Xiaoming(Department of Disease Control and Prevention,Wuyishan Center for Disease Control and Prevention,Wuyishan 354300,Fujian,China)

机构地区：[1]武夷山市疾病预防控制中心疾控科,福建武夷山354300

出　　处：《中国药物滥用防治杂志》2024年第12期2306-2307,共2页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:研究结核病合并艾滋病患者应用抗病毒药物治疗以及利福布汀联合治疗的效果和安全性。方法:选取2022年4月—2023年12月本院64例结核病合并艾滋病患者为研究对象,经过随机数表法分为对照组和观察组,每组32例。对照组予以抗病毒药物^(+)利福平治疗,观察组予以抗病毒药物^(+)利福布汀治疗,比较两组临床疗效、炎症因子、T淋巴细胞水平及不良反应发生情况。结果:观察组治疗有效率(96.88%)较对照组(75.00%)提高(P<0.05)。观察组治疗后CRP、IL-6、TNF-α、CD4^(+)、CD8^(+)低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:对于结核病合并艾滋病患者,利福布汀联合治疗能够提高疗效,有效调节免疫力,并改善炎症反应,且不会增加不良反应。Objective:To study the effect and safety of antiviral drug treatment in tuberculosis patients with AIDS.Methods:A total of 64 patients with tuberculosis complicated with AIDS in our hospital from April 2022 to December 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 32 patients in each group.The control group was treated with antiviral drugs^(+)rifampicin,and the observation group was treated with antiviral drugs^(+)rifabutin.The clinical efficacy,inflammatory factors,T lymphocyte levels and adverse reactions were compared between the two groups.Results:The effective rate of treatment in the observation group(96.88%)was higher than that in the control group(75.00%)(P<0.05).After treatment,CRP,IL-6,TNF-a,CD4 and CD8^(+)in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:For patients with tuberculosis and AIDS,rifabutin combination therapy can improve the efficacy,effectively regulate immunity,and improve the inflammatory response,without increasing adverse reactions.

关 键 词：艾滋病 结核病 利福布汀 炎症反应 免疫功能 

分 类 号：R52[医药卫生—内科学]